Alphabet’s life sciences arm, Verily, is partnering with the digital pathology platform Lumea to improve the objectivity and efficiency of prostate cancer diagnosis, prognosis, and therapy selection. Verily developed AI systems for…
TruCore Pathology is a team of board-certified, expert pathologists. They use Lumea’s proprietary tissue-handling technology to get larger, higher-quality samples that increase cancer detection. Lumea is advancing pathology into the…
Matthew Leavitt, MD, just co-founded the DDx Foundation. He aims to progress prostate cancer research and treatment through digital diagnostics. The other founders are pathologists E. David Crawford, MD, and…
Matthew Leavitt, MD, Lumea Founder, had the opportunity to speak at Cambridge Health Institute’s 7th annual Digital Pathology Conference. This Cambridge conference focused on transforming medicine in a digital world. “Seven…
PathNet uses Lumea digital pathology tech in its practices. PathNet is a coalition of independent pathology groups founded for pathologists by pathologists. Their united goal is to leverage Lumea’s digital…
*BxLink has not been approved by the FDA for digital primary diagnosis. Refer to CAP guidelines regarding the use of digital pathology technologies.
